Literature DB >> 17003497

H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signaling.

Irina Nazarenko1, Glen Kristiansen, Sabine Fonfara, Raphaela Guenther, Cornelia Gieseler, Wolfgang Kemmner, Reinhold Schafer, Iver Petersen, Christine Sers.   

Abstract

H-REV107-1, a known member of the class II tumor suppressor gene family, is involved in the regulation of differentiation and survival. We analyzed H-REV107-1 in non-small cell lung carcinomas, in normal lung, and in immortalized and tumor-derived cell lines. Sixty-eight percent of lung tumors revealed positive H-REV107-1-specific staining. Furthermore, survival analysis demonstrated a significant association of cytoplasmic H-REV107-1 with decreased patient survival. This suggested that H-REV107-1, known as a tumor suppressor, plays a different role in non-small cell lung carcinomas. Knock-down of H-REV107-1 expression in lung carcinoma cells inhibited anchorage-dependent and anchorage-independent growth whereas overexpression of H-REV107-1 induced tumor cell proliferation. Consistent with results of the survival analysis, cytoplasmic localization of the protein was essential for this growth-inducing function. Analysis of signaling pathways potentially involved in this process demonstrated that overexpression of H-REV107-1 stimulated RAS-GTPase activity, ERK1,2 phosphorylation, and caveolin-1 expression in the cell lines analyzed. These results indicate that H-REV107-1 is deficient in its function as a tumor suppressor in non-small cell lung carcinomas and is required for proliferation and anchorage-independent growth in cells expressing high levels of the protein, thus contributing to tumor progression in a subset of non-small cell lung carcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003497      PMCID: PMC1698850          DOI: 10.2353/ajpath.2006.051341

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

Review 1.  Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.

Authors:  S K Chan; W J Gullick; M E Hill
Journal:  Eur J Cancer       Date:  2006-01       Impact factor: 9.162

2.  Clara cell secretory protein-expressing cells of the airway neuroepithelial body microenvironment include a label-retaining subset and are critical for epithelial renewal after progenitor cell depletion.

Authors:  K U Hong; S D Reynolds; A Giangreco; C M Hurley; B R Stripp
Journal:  Am J Respir Cell Mol Biol       Date:  2001-06       Impact factor: 6.914

3.  Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model.

Authors:  H Y Shi; W Zhang; R Liang; S Abraham; F S Kittrell; D Medina; M Zhang
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

4.  Identification of silencing of nine genes in human gastric cancers.

Authors:  Atsushi Kaneda; Michio Kaminishi; Kazuyoshi Yanagihara; Takashi Sugimura; Toshikazu Ushijima
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

5.  Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.

Authors:  Kyoji Hirai; Kiyoshi Koizumi; Shuji Haraguchi; Tomomi Hirata; Iwao Mikami; Mitsuhiro Fukushima; Shigeki Yamagishi; Tetsuo Kawashima; Daisuke Okada; Kazuo Shimizu; Masashi Kawamoto
Journal:  Ann Thorac Surg       Date:  2005-01       Impact factor: 4.330

6.  The paradoxical expression of maspin in ovarian carcinoma.

Authors:  Anil K Sood; Mavis S Fletcher; Lynn M Gruman; Jeremy E Coffin; Sarvenaz Jabbari; Zhila Khalkhali-Ellis; Nancy Arbour; Elisabeth A Seftor; Mary J C Hendrix
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

7.  The p21 ras C-terminus is required for transformation and membrane association.

Authors:  B M Willumsen; A Christensen; N L Hubbert; A G Papageorge; D R Lowy
Journal:  Nature       Date:  1984 Aug 16-22       Impact factor: 49.962

8.  Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12.

Authors:  K Husmann; C Sers; E Fietze; A Mincheva; P Lichter; R Schäfer
Journal:  Oncogene       Date:  1998-09-10       Impact factor: 9.867

9.  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.

Authors:  Mitsuo Sato; Melville B Vaughan; Luc Girard; Michael Peyton; Woochang Lee; David S Shames; Ruben D Ramirez; Noriaki Sunaga; Adi F Gazdar; Jerry W Shay; John D Minna
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

10.  ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

Authors:  S Vicent; J M López-Picazo; G Toledo; M D Lozano; W Torre; C Garcia-Corchón; C Quero; J-C Soria; S Martín-Algarra; R G Manzano; L M Montuenga
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

View more
  13 in total

1.  Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.

Authors:  Shunbin Xiong; Huolin Tu; Madhusudhan Kollareddy; Vinod Pant; Qin Li; Yun Zhang; James G Jackson; Young-Ah Suh; Ana C Elizondo-Fraire; Peirong Yang; Gilda Chau; Mehrnoosh Tashakori; Amanda R Wasylishen; Zhenlin Ju; Hilla Solomon; Varda Rotter; Bin Liu; Adel K El-Naggar; Lawrence A Donehower; Luis Alfonso Martinez; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

2.  High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer.

Authors:  Xueli Yang; Zhengquan Zhang; Xiaoqing Jia; Yanqin Zhang; Tianyang Mu; Bingzheng Zhou; Lin Li; Deyuan Fu; Xin Hu; Shunbin Xiong
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

3.  Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA).

Authors:  Robin E Duncan; Eszter Sarkadi-Nagy; Kathy Jaworski; Maryam Ahmadian; Hei Sook Sul
Journal:  J Biol Chem       Date:  2008-07-09       Impact factor: 5.157

4.  Relationship between polymorphisms of the lipid metabolism-related gene PLA2G16 and risk of colorectal cancer in the Chinese population.

Authors:  Xiao-Nv Xie; Jing Yu; Li-Hua Zhang; Zhi-Ying Luo; Dong-Sheng Ouyang; Ling-Jie Zheng; Chun-Yang Wang; Li Yang; Ling Chen; Zhi-Rong Tan
Journal:  Funct Integr Genomics       Date:  2018-10-20       Impact factor: 3.410

5.  PLA2G16 Expression in Human Osteosarcoma Is Associated with Pulmonary Metastasis and Poor Prognosis.

Authors:  Shoulei Liang; Zhiwu Ren; Xiuxin Han; Jilong Yang; Luling Shan; Lin Li; Binying Wang; Qianyi Zhang; Tianyang Mu; Kexin Chen; Shunbin Xiong; Guowen Wang
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

6.  H-rev107 regulates prostaglandin D2 synthase-mediated suppression of cellular invasion in testicular cancer cells.

Authors:  Rong-Yaun Shyu; Chang-Chieh Wu; Chun-Hua Wang; Tzung-Chieh Tsai; Lu-Kai Wang; Mao-Liang Chen; Shun-Yuan Jiang; Fu-Ming Tsai
Journal:  J Biomed Sci       Date:  2013-05-20       Impact factor: 8.410

7.  Induction of apoptosis by the retinoid inducible growth regulator RIG1 depends on the NC motif in HtTA cervical cancer cells.

Authors:  Fu-Ming Tsai; Rong-Yaun Shyu; Su-Ching Lin; Chang-Chieh Wu; Shun-Yuan Jiang
Journal:  BMC Cell Biol       Date:  2009-02-26       Impact factor: 4.241

Review 8.  The HRASLS (PLA/AT) subfamily of enzymes.

Authors:  Emily B Mardian; Ryan M Bradley; Robin E Duncan
Journal:  J Biomed Sci       Date:  2015-10-26       Impact factor: 8.410

9.  Phospholipase A/Acyltransferase enzyme activity of H-rev107 inhibits the H-RAS signaling pathway.

Authors:  Chun-Hua Wang; Rong-Yaun Shyu; Chang-Chieh Wu; Tzung-Chieh Tsai; Lu-Kai Wang; Mao-Liang Chen; Shun-Yuan Jiang; Fu-Ming Tsai
Journal:  J Biomed Sci       Date:  2014-05-01       Impact factor: 8.410

10.  PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

Authors:  Lin Li; Shoulei Liang; Amanda R Wasylishen; Yanqin Zhang; Xueli Yang; Bingzheng Zhou; Luling Shan; Xiuxin Han; Tianyang Mu; Guowen Wang; Shunbin Xiong
Journal:  Oncotarget       Date:  2016-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.